LON:POLB Poolbeg Pharma (POLB) Share Price, News & Analysis GBX 2.53 -0.02 (-0.67%) As of 11:49 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Poolbeg Pharma Stock (LON:POLB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Poolbeg Pharma alerts:Sign Up Key Stats Today's Range 2.50▼ 2.6050-Day Range 2.55▼ 3.6052-Week Range 2.25▼ 13.20Volume1.98 million shsAverage Volume2.18 million shsMarket Capitalization£13.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. Poolbeg comprises a strong and growing portfolio of development assets. Read More Receive POLB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Poolbeg Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address POLB Stock News HeadlinesSMALL CAP IDEA: Poolbeg Pharma raises £4.1m to finance cancer drugsJune 2, 2025 | msn.comPoolbeg Pharma shares plummet as Hookipa walks away from possible bidFebruary 21, 2025 | lse.co.ukThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”August 8 at 2:00 AM | Weiss Ratings (Ad)Poolbeg Agrees to Bid Deadline Extension for Possible Hookipa Pharma DealJanuary 30, 2025 | marketwatch.comGilead gives its blessing to Poolbeg Pharma’s Hookpia merger dealJanuary 7, 2025 | msn.comPoolbeg Pharma to merge with Austrian biotech companyJanuary 2, 2025 | msn.comHookipa Pharma to acquire Poolbeg PharmaJanuary 2, 2025 | msn.comPoolbeg Pharma’s POLB 001 Shows Promise in CRS TreatmentDecember 9, 2024 | markets.businessinsider.comSee More Headlines POLB Stock Analysis - Frequently Asked Questions How have POLB shares performed this year? Poolbeg Pharma's stock was trading at GBX 7.10 at the beginning of 2025. Since then, POLB stock has decreased by 64.3% and is now trading at GBX 2.53. How were Poolbeg Pharma's earnings last quarter? Poolbeg Pharma PLC (LON:POLB) announced its earnings results on Tuesday, May, 20th. The company reported ($1.16) EPS for the quarter. How do I buy shares of Poolbeg Pharma? Shares of POLB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Poolbeg Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Poolbeg Pharma investors own include EQTEC (EQT), Great Western Mining (GWMO), Power Metal Resources (POW), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), Alzamend Neuro (ALZN) and Alpine 4 (ALPP). Company Calendar Last Earnings5/20/2025Today8/08/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:POLB CIKN/A Webwww.poolbegpharma.com Phone44 20 7183 1499FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (851.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£4.50 billion Net MarginsN/A Pretax MarginN/A Return on Equity-32.56% Return on Assets-21.33% Debt Debt-to-Equity RatioN/A Current Ratio19.61 Quick Ratio47.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 1.20 per share Price / Cash Flow2.11 Book ValueGBX 2,489.80 per share Price / Book0.00Miscellaneous Outstanding Shares513,958,333Free FloatN/AMarket Cap£13.03 million OptionableNot Optionable Beta2.11 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (LON:POLB) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poolbeg Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Poolbeg Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
